VolitionRX Ltd（VNRX）股票分析VNRXVolitionRX Ltd

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

VolitionRX Ltd (VNRX) is currently priced at $0.4493, which is significantly below the analyst price target of $4 from Maxim, indicating potential upside. However, the stock has a low RSI of 44.471, suggesting it is not yet oversold, and a recent 5-day change of +7.77% shows some positive momentum. The main risk is the company's negative net income, which was -$7,326,047 in Q2 2026, indicating ongoing financial challenges that could affect future performance.

3 analysts cover VNRX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 2.25.